Figure 2.

Median survival time (MST) and outcome assessment of virotherapy. The time each patient was enrolled in the study (green) or dropped out of the trial (gray), to represent overall survival, is shown. The inoculation of the virus (O) and the outcome assessment following RECIST criteria are represented only if there was a change of category reported. The baseline measurements were taken before each ICOCAV15 dose, and disease evolution was classified as partial response (PR), stable disease (SD), and progressive disease (PD). The patients’ survival time (death; X) and the MST with standard of care for each tumor type (+) are shown.